Deuterated etravirine
US8410124B2 · kind B2 · utility
8Cited by
10References
15Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 17, 2008 |
| Grant date | Apr 2, 2013 |
| Priority date | — |
| Expiry date | May 22, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure relates to novel di-aryl-pyrimidine (DAPY) compounds and pharmaceutically acceptable salts thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.